Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937737 | 0.88 | ALDH1A1 (0.35) | SMN1; SMN2HDAC1KMT2AALDH1A1POLB | |
| SCHEMBL19937738 | 0.85 | ALDH1A1 (0.46) | SMN1; SMN2KMT2AALDH1A1POLB | |
| SCHEMBL15758840 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL15758042 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL19961476 | 0.84 | OPRK1 (0.31) | — | |
| SCHEMBL19937736 | 0.81 | PTP4A3 (0.35) | SMN1; SMN2MAPTKMT2AALDH1A1POLB | |
| SCHEMBL18084012 | 0.80 | KMT2A (0.41) | SMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL20663374 | 0.79 | SMN1; SMN2 (0.35) | SMN1; SMN2MAPTHDAC1HDAC8 | |
| SCHEMBL15765005 | 0.79 | CA12 (0.44) | MAPT | |
| SCHEMBL19937739 | 0.77 | OPRD1 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065950-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065950-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | OPRL1, PDE3A, TRPV1 | SMN1; SMN2 69/4885MAPT 1318/4885HDAC1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.